MARKET
IPO

JUNS

JUPITER NEUROSCIENCES, INC.
JUNS
NASDAQ
Upcoming IPOs
Expected Listing Date: 2024-11-22
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-49.60~-39.68
58.31~72.89
-20.62~-16.49
131.51M~164.38M
Biotechnology & Medical Research
2022-02-02
Public Filing
View Prospectus
Pending
Offering
Price Range: 4.00~5.00
Shares to be Issued: 2500.00K
2024-11-21
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 32.88M
2024-11-22
Listed
No Data
About JUNS
Jupiter Neurosciences, Inc., formerly Jupiter Orphan Therapeutics, Inc., is a clinical stage research and development pharmaceutical company. The Company develops a resveratrol platform product targeting treatment of neuro-inflammation. The Company's product candidate, JOTROL, which primarily targets mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as amyotrophic lateral sclerosis (ALS) which is in an early development stage. The JOTROL delivery platform allows resveratrol to be consumed in a soft gel capsule form. It offers therapeutic benefit to central nervous system diseases such as Alzheimer’s disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. It targets Mild Cognitive Impairment/early Alzheimer’s disease with traumatic brain injury (TBI)/concussions and Covid-19 in early development stages. The Company's product candidate, JOTROL, is in Phase I clinical trial.

Webull offers JUPITER NEUROSCIENCES, INC. stock information, including NASDAQ: JUNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JUNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JUNS stock methods without spending real money on the virtual paper trading platform.